技术资料
-
(Sep 2024) Aging (Albany NY) 16 18Frailty and pre-frailty associated with long-term diminished physical performance and quality of life in breast cancer and hematopoietic cell transplant survivors
Physical frailty as a sign of accelerated aging is not well characterized in breast cancer (BC) and hematopoietic cell transplant (HCT) survivors and its correlation with outcomes and quality of life (QOL) is not defined. We conducted a prospective study to determine the prevalence of frailty in adult BC and HCT survivors,examine its impact on QOL,and determine its association with p16INK4a,a molecular biomarker for biological aging. The study included 59 BC and 65 HCT survivors. Median age was 60 years (range 27-81),68.5% were female and 49.2% were 18-59 vs. 51.8% ≥60 years old. A total of 71 (57.3%) were “fit” (frailty score 0) vs. 53 (42.7%) were pre-frailty/frail (frailty scores ≥1),and of the latter 17 (32.1%) were BC and 36 (67.9%) HCT patients. On multivariate analysis,patients >60 years were twice as likely to be frail (OR 2.04,95% CI,0.96-4.33; p=0.07),HCT were more likely to be frail compared to BC patients,and female HCT had 2.43 (95% CI,0.92-6.40) and male HCT patients had 3.25 (95% CI,1.37-7.72) times higher risk of frail; p=0.02. Frailty was associated with significant decline in QOL,measured by Medical Outcomes Study (MOS) Short Form 36 (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS),and FACT (Functional Assessment of Cancer Therapy) scores. p16INK4a expression was higher in those who were frail,older than 60,and with higher expression in frail vs. fit patients who are 18-59 years. Our study highlights the high prevalence of frailty in survivors with detrimental effects on physical and overall wellbeing,and supports an association between frailty and the senescence marker p16INK4a. View Publication -
(Oct 2024) Journal of Translational Medicine 22 10299FANCA promotes lung adenocarcinoma progression and is a potential target for epitope vaccine immunotherapy
BackgroundFANCA mutations have been detected in a variety of cancers and found to be pro-carcinogenic. However,no functional studies have been identified regarding the involvement of FANCA in the occurrence and the immune response of LUAD.MethodsThe mRNA expression and overall survival rates of FANCA were evaluated by the TIMER,PrognoScan and TCGA database in LUAD tissues,and FANCA expression was further validated by clinical serum samples using ELISA. The correlation between FANCA and immune infiltration level was investigated via TISIDB database and CIBERSORT algorithm. The Kaplan–Meier plotter was used to further evaluate the prognostic value based on the expression levels of FANCA in related immune cells. Then,the influence of FANCA knockout on the proliferation,migration,and invasion of A549 and H1299 cells was validated using CCK8,cloning formation,and Transwell assays. Subsequently,HLA-A2-restricted FANCA antigenic peptides were predicted and synthesized by NetMHC4.0 and SYFPEITHI,and DCs were induced and cultured in vitro. Finally,DCs loaded with HLA-A2-restricted FANCA antigenic peptides were co-cultured with autologous peripheral blood lymphocyte to generate specific CTLs. The killing effects of different CTLs on LUAD cells were studied.ResultsThe results showed that high levels of FANCA in patients with LUAD were significantly correlated with worse OS survival,which was correlated with age,clinical stage,pathological T stage,M stage,and N stage in LUAD. Knockdown of FANCA in A549 and H1299 cells significantly inhibited proliferation,metastasis,and invasion in vitro. In addition,FANCA was significantly related to immune infiltrate,genomic alterations and TMB. FANCA expression infuenced the prognosis of LUAD patients by directly affecting immune cell infltration. Finally,HLA-A2-restricted FANCA antigenic peptides were synthesized. And FANCA 146–154 (SLLEFAQYL) antigenic peptide exhibit a stronger affinity for DCs,and induce CTLs to produce stronger targeted killing ability for LUAD cells at an effector-to-target ratio of 40:1.ConclusionThese results demonstrated that the elevation of FANCA promotes malignant phenotype of LUAD,and the potential peptide P2 (SLLEFAQYL) derived from FANCA may be used as an epitope vaccine for the treatment of LUAD. View Publication -
(Sep 2024) Frontiers in Immunology 15SARS-CoV-2 spike protein induces the cytokine release syndrome by stimulating T cells to produce more IL-2
IntroductionCytokine release syndrome (CRS) is one of the leading causes of mortality in patients with COVID-19 caused by the SARS-CoV-2 coronavirus. However,the mechanism of CRS induced by SARS-CoV-2 is vague.MethodsUsing spike protein combined with IL-2,IFN-γ,and TNF-α to stimulate human peripheral blood mononuclear cells (PBMCs) to secrete CRS-related cytokines,the content of cytokines in the supernatant was detected,and the effects of NK,T,and monocytes were analyzed.ResultsThis study shows that dendritic cells loaded with spike protein of SARS-CoV-2 stimulate T cells to release much more interleukin-2 (IL-2,) which subsequently cooperates with spike protein to facilitate PBMCs to release IL-1β,IL-6,and IL-8. These effects are achieved via IL-2 stimulation of NK cells to release tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ),as well as T cells to release IFN-γ Mechanistically,IFN-γ and TNF-α enhance the transcription of CD40,and the interaction of CD40 and its ligand stabilizes the membrane expression of toll-like receptor 4 (TLR4) that serves as a receptor of spike protein on the surface of monocytes. As a result,there is a constant interaction between spike protein and TLR4,leading to continuous activation of nuclear factor-κ-gene binding (NF-κB). Furthermore,TNF-α also activates NF-κB signaling in monocytes,which further cooperates with IFN-γ and spike protein to modulate NF-κB–dependent transcription of CRS-related inflammatory cytokines.DiscussionTargeting TNF-α/IFN-γ in combination with TLR4 may represent a promising therapeutic approach for alleviating CRS in individuals with COVID-19. View Publication -
(Oct 2024) Cell Discovery 10Developing an erythrocyte‒MHC-I conjugate for cancer treatment
Mature erythrocytes are known to lack major histocompatibility complex (MHC) proteins. However,the presence of MHC molecules on erythrocytes has been occasionally reported,though without a defined function. In this study,we designed erythrocyte conjugated solely with a fusion protein consisting of an antigenic peptide linked to MHC class I (MHC-I) protein,termed MHC-I‒Ery. The modified erythrocyte,decorated with the peptide derived from human papillomavirus (HPV) 16 oncoprotein E6/E7,effectively activated antigen-specific CD8+ T cells in peripheral blood mononuclear cells (PBMCs) from HPV16+ cervical cancer patients. Additionally,MHC-I‒Ery monotherapy was shown to inhibit antigen-positive tumor growth in mice. This treatment immediately activated CD8+ T cells and reduced suppressive myeloid cells in the spleen,leading to systemic anti-tumor activity. Safety and tolerability evaluations of MHC-I‒Ery in non-human primates further supported its clinical potential. Our results first demonstrated that erythrocytes equipped solely with antigen peptide‒MHC-I complexes can robustly stimulate the immune system,suggesting a novel and promising approach for advancing cancer immunotherapy. View Publication -
(Sep 2024) Communications Biology 7Full-length single-cell BCR sequencing paired with RNA sequencing reveals convergent responses to pneumococcal vaccination
Single-cell RNA sequencing (scRNA-seq) can resolve transcriptional features from individual cells,but scRNA-seq techniques capable of resolving the variable regions of B cell receptors (BCRs) remain limited,especially from widely-used 3′-barcoded libraries. Here,we report a method that can recover paired,full-length variable region sequences of BCRs from 3′-barcoded scRNA-seq libraries. We first verify this method (B3E-seq) can produce accurate,full-length BCR sequences. We then apply this method to profile B cell responses elicited against the capsular polysaccharide of Streptococcus pneumoniae serotype 3 (ST3) by glycoconjugate vaccines in five infant rhesus macaques. We identify BCR features associated with specificity for the ST3 antigen which are present in multiple vaccinated monkeys,indicating a convergent response to vaccination. These results demonstrate the utility of our method to resolve key features of the B cell repertoire and profile antigen-specific responses elicited by vaccination. A method that recovers full-length,paired heavy- and light-chain variable regions of B cell receptor transcripts from 3’barcoded scRNA-seq libraries reveals a convergent response to pneumococcus vaccination in rhesus macaques. View Publication -
(Sep 2024) Frontiers in Immunology 15 10Pregnancy-related factors induce immune tolerance through regulation of sCD83 release
A well-balanced maternal immune system is crucial to maintain fetal tolerance in case of infections during pregnancy. Immune adaptations include an increased secretion of soluble mediators to protect the semi-allogeneic fetus from excessive pro-inflammatory response. B lymphocytes acquire a higher capacity to express CD83 and secrete soluble CD83 (sCD83) upon exposure to bacteria-derived components such as LPS. CD83 possesses immune modulatory functions and shows a promising therapeutic potential against inflammatory conditions. The administration of sCD83 to pregnant mice reduces LPS-induced abortion rates. The increased CD83 expression by endometrial B cells as compared to peripheral blood B cells suggests its modulatory role in the fetal tolerance,especially in the context of infection. We postulate that in pregnancy,CD83 expression and release is controlled by pregnancy-related hormones. The intra- and extracellular expression of CD83 in leukocytes from peripheral blood or decidua basalis and parietalis at term were analyzed by flow cytometry. After treatment with pregnancy-related hormones and LPS,ELISA and qPCR were performed to study sCD83 release and CD83 gene expression,respectively. Cleavage prediction analysis was used to find potential proteases targeting CD83. Expression of selected proteases was analyzed by ELISA. Higher levels of CD83 were found in CD11c+ dendritic cells,CD3+ T cells and CD19+ B cells from decidua basalis and decidua parietalis after LPS-stimulation in vitro. An increase of intracellular expression of CD83 was also detected in CD19+ B cells from both compartments. Stimulated B cells displayed significantly higher percentages of CD83+ cells than dendritic cells and T cells from decidua basalis and peripheral blood. Treatment of B lymphocytes with pregnancy-related molecules (E2,P4,TGF-β1 and hCG) enhanced the LPS-mediated increase of CD83 expression,while dexamethasone led to a reduction. Similarly,the release of sCD83 was increased under TGF-β1 treatment but decreased upon dexamethasone stimulation. Finally,we found that the hormonal regulation of CD83 expression is likely a result from a balance between gene transcription from CD83 and the modulation of the metalloproteinase MMP-7. Thus,data supports and complements our previous murine studies on hormonal regulation of CD83 expression,reinforcing its immunomodulatory relevance in anti-bacterial responses during pregnancy. View Publication -
(Sep 2024) PLOS Pathogens 20 9Release of P-TEFb from the Super Elongation Complex promotes HIV-1 latency reversal
The persistence of HIV-1 in long-lived latent reservoirs during suppressive antiretroviral therapy (ART) remains one of the principal barriers to a functional cure. Blocks to transcriptional elongation play a central role in maintaining the latent state,and several latency reversal strategies focus on the release of positive transcription elongation factor b (P-TEFb) from sequestration by negative regulatory complexes,such as the 7SK complex and BRD4. Another major cellular reservoir of P-TEFb is in Super Elongation Complexes (SECs),which play broad regulatory roles in host gene expression. Still,it is unknown if the release of P-TEFb from SECs is a viable latency reversal strategy. Here,we demonstrate that the SEC is not required for HIV-1 replication in primary CD4+ T cells and that a small molecular inhibitor of the P-TEFb/SEC interaction (termed KL-2) increases viral transcription. KL-2 acts synergistically with other latency reversing agents (LRAs) to reactivate viral transcription in several cell line models of latency in a manner that is,at least in part,dependent on the viral Tat protein. Finally,we demonstrate that KL-2 enhances viral reactivation in peripheral blood mononuclear cells (PBMCs) from people living with HIV (PLWH) on suppressive ART,most notably in combination with inhibitor of apoptosis protein antagonists (IAPi). Taken together,these results suggest that the release of P-TEFb from cellular SECs may be a novel route for HIV-1 latency reactivation. Author summarySince the start of the HIV pandemic,it is estimated that nearly 86 million people have been infected with the virus,and about 40 million people have died. Modern antiretroviral therapies potently restrict viral replication and prevent the onset of AIDS,saving millions of lives. However,these therapies are not curative due to the persistence of the virus in a silenced or ‘latent’ state in long-lived cells of the body. One proposed strategy to clear this latent reservoir,termed “shock and kill”,is to activate these silenced viruses such that the infected cells can be cleared from the body by the immune system. While several drugs have been developed that can activate latent viruses,none have proven effective at reducing the size of the latent reservoir in patients in clinical trials. Here,we describe a new method for latency reactivation using a small molecule inhibitor of a human protein complex called the Super Elongation Complex (SEC). Inhibiting the SEC enhances viral transcription during active infection and triggers the reactivation of latent viruses,especially when in combination with other latency reversing agents. These results pave the way for developing more effective strategies to reactivate latent viruses towards a functional cure. View Publication -
(Sep 2024) Nature Communications 15Sequence variants influencing the regulation of serum IgG subclass levels
Immunoglobulin G (IgG) is the main isotype of antibody in human blood. IgG consists of four subclasses (IgG1 to IgG4),encoded by separate constant region genes within the Ig heavy chain locus (IGH). Here,we report a genome-wide association study on blood IgG subclass levels. Across 4334 adults and 4571 individuals under 18 years,we discover ten new and identify four known variants at five loci influencing IgG subclass levels. These variants also affect the risk of asthma,autoimmune diseases,and blood traits. Seven variants map to the IGH locus,three to the Fcγ receptor (FCGR) locus,and two to the human leukocyte antigen (HLA) region,affecting the levels of all IgG subclasses. The most significant associations are observed between the G1m (f),G2m(n) and G3m(b*) allotypes,and IgG1,IgG2 and IgG3,respectively. Additionally,we describe selective associations with IgG4 at 16p11.2 (ITGAX) and 17q21.1 (IKZF3,ZPBP2,GSDMB,ORMDL3). Interestingly,the latter coincides with a highly pleiotropic signal where the allele associated with lower IgG4 levels protects against childhood asthma but predisposes to inflammatory bowel disease. Our results provide insight into the regulation of antibody-mediated immunity that can potentially be useful in the development of antibody based therapeutics. Immunoglobulin G (IgG) is the main isotype of antibody in human blood. Here the authors describe 14 genetic variants that affect IgG levels in blood. The data provide new insight into the regulation of humoral immunity that could be useful in the development of antibody-based therapeutics. View Publication -
(Sep 2024) Nature Cardiovascular Research 3 9Endothelial γ-protocadherins inhibit KLF2 and KLF4 to promote atherosclerosis
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide. Laminar shear stress from blood flow,sensed by vascular endothelial cells,protects from ASCVD by upregulating the transcription factors KLF2 and KLF4,which induces an anti-inflammatory program that promotes vascular resilience. Here we identify clustered γ-protocadherins as therapeutically targetable,potent KLF2 and KLF4 suppressors whose upregulation contributes to ASCVD. Mechanistic studies show that γ-protocadherin cleavage results in translocation of the conserved intracellular domain to the nucleus where it physically associates with and suppresses signaling by the Notch intracellular domain. γ-Protocadherins are elevated in human ASCVD endothelium; their genetic deletion or antibody blockade protects from ASCVD in mice without detectably compromising host defense against bacterial or viral infection. These results elucidate a fundamental mechanism of vascular inflammation and reveal a method to target the endothelium rather than the immune system as a protective strategy in ASCVD. Joshi et al. show that γ-protocadherins suppress the anti-inflammatory KLF2 and KLF4 pathway and that targeting them is a viable therapeutic strategy to protect against atherosclerosis. View Publication -
(Sep 2024) BMC Medicine 22A systems serology approach to identifying key antibody correlates of protection from cerebral malaria in Malawian children
BackgroundPlasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) proteins are expressed on the surface of infected erythrocytes,mediating parasite sequestration in the vasculature. PfEMP1 is a major target of protective antibodies,but the features of the antibody response are poorly defined.MethodsIn Malawian children with cerebral or uncomplicated malaria,we characterized the antibody response to 39 recombinant PfEMP1 Duffy binding like (DBL) domains or cysteine-rich interdomain regions (CIDRs) in detail,including measures of antibody classes,subclasses,and engagement with Fcγ receptors and complement. Using elastic net regularized logistic regression,we identified a combination of seven antibody targets and Fc features that best distinguished between children with cerebral and uncomplicated malaria. To confirm the role of the selected targets and Fc features,we measured antibody-dependent neutrophil and THP-1 cell phagocytosis of intercellular adhesion molecule-1 (ICAM-1) and endothelial protein C (EPCR) co-binding infected erythrocytes.ResultsThe selected features distinguished between children with cerebral and uncomplicated malaria with 87% accuracy (median,80–96% interquartile range) and included antibody to well-characterized DBLβ3 domains and a less well-characterized CIDRγ12 domain. The abilities of antibodies to engage C1q and FcγRIIIb,rather than levels of IgG,correlated with protection. In line with a role of FcγRIIIb binding antibodies to DBLβ3 domains,antibody-dependent neutrophil phagocytosis of ICAM-1 and EPCR co-binding IE was higher in uncomplicated malaria (15% median,8–38% interquartile range) compared to cerebral malaria (7%,30–15%,p < 0.001).ConclusionsAntibodies associated with protection from cerebral malaria target a subset of PfEMP1 domains. The Fc features of protective antibody response include engagement of FcγRIIIb and C1q,and ability to induce antibody-dependent neutrophil phagocytosis of infected erythrocytes. Identifying the targets and Fc features of protective immunity could facilitate the development of PfEMP1-based therapeutics for cerebral malaria.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12916-024-03604-8. View Publication -
(Sep 2024) Scientific Reports 14 Suppl 5Seminal plasma inhibits Chlamydia trachomatis infection in vitro, and may have consequences on mucosal immunity
Seminal plasma (SP) is the main vector of C. trachomatis (CT) during heterosexual transmission from male to female. It has immunomodulatory properties and impacts the susceptibility to HIV-1 infection,but its role has not been explored during CT infection. In the female reproductive tract (FRT),CT infection induces cytokine production and neutrophil recruitment. The role of neutrophils during CT infection is partially described,they could be at the origin of the pathology observed during CT infection. During this study,we developed an experimental in vitro model to characterize the impact of CT infection and SP on endocervical epithelial cell immune response in the FRT. We also studied the impact of the epithelial cell response on neutrophil phenotype and functions. We showed that the production by epithelial cells of pro-inflammatory cytokines increased during CT infection. Moreover,the pool of SP as well as individuals SP inhibited CT infection in a dose-dependent manner. The pool of SP inhibited cytokine production in a dose-dependent manner. The pool of SP altered gene expression profiles of infected cells. The culture supernatants of cells infected or not with CT,in presence or not of the pool of SP,had an impact on neutrophil phenotype and functions: they affected markers of neutrophil maturation,activation and adhesion capacity,as well as the survival,ROS production and phagocytosis ability. This study proposes a novel approach to study the impact of the environment on the phenotype and functions of neutrophils in the FRT. It highlights the impact of the factors of the FRT environment,in particular SP and CT infection,on the mucosal inflammation and the need to take into account the SP component while studying sexually transmitted infections during heterosexual transmission from male to female. View Publication -
(Sep 2024) Nature Communications 15Local administration of regulatory T cells promotes tissue healing
Regulatory T cells (Tregs) are crucial immune cells for tissue repair and regeneration. However,their potential as a cell-based regenerative therapy is not yet fully understood. Here,we show that local delivery of exogenous Tregs into injured mouse bone,muscle,and skin greatly enhances tissue healing. Mechanistically,exogenous Tregs rapidly adopt an injury-specific phenotype in response to the damaged tissue microenvironment,upregulating genes involved in immunomodulation and tissue healing. We demonstrate that exogenous Tregs exert their regenerative effect by directly and indirectly modulating monocytes/macrophages (Mo/MΦ) in injured tissues,promoting their switch to an anti-inflammatory and pro-healing state via factors such as interleukin (IL)-10. Validating the key role of IL-10 in exogenous Treg-mediated repair and regeneration,the pro-healing capacity of these cells is lost when Il10 is knocked out. Additionally,exogenous Tregs reduce neutrophil and cytotoxic T cell accumulation and IFN-γ production in damaged tissues,further dampening the pro-inflammatory Mo/MΦ phenotype. Highlighting the potential of this approach,we demonstrate that allogeneic and human Tregs also promote tissue healing. Together,this study establishes exogenous Tregs as a possible universal cell-based therapy for regenerative medicine and provides key mechanistic insights that could be harnessed to develop immune cell-based therapies to enhance tissue healing. Regulatory T cells (Tregs) are known for suppressing inflammatory processes,but their full capacity for tissue regeneration is yet to be harnessed. Here,the authors demonstrate the efficiency of Tregs in facilitating tissue healing in mouse models of bone,muscle,and skin injury,with monocytes/macrophages and interleukin-10 playing a key mechanistic role in the process. View Publication
过滤器
筛选结果
产品类型
- 仪器及软件
Show More
Show Less
研究领域
- HIV 70 项目
- HLA 52 项目
- 上皮细胞生物学 269 项目
- 免疫 1012 项目
- 内皮细胞研究 1 项目
- 呼吸系统研究 48 项目
- 嵌合体 25 项目
- 干细胞生物学 2827 项目
- 感染性疾病(传染病) 7 项目
- 抗体制备 7 项目
- 新陈代谢 7 项目
- 杂交瘤制备 2 项目
- 疾病建模 248 项目
- 癌症 6 项目
- 神经科学 650 项目
- 移植研究 100 项目
- 类器官 178 项目
- 细胞外囊泡研究 10 项目
- 细胞治疗开发 18 项目
- 细胞疗法开发 113 项目
- 细胞系制备 191 项目
- 脐带血库 64 项目
- 血管生成细胞研究 1 项目
- 传染病 64 项目
- 内皮细胞生物学 7 项目
- 杂交瘤生成 14 项目
- 癌症研究 724 项目
- 血管生成细胞研究 51 项目
Show More
Show Less
产品系列
- ALDECOUNT 14 项目
- CellPore 11 项目
- CellShield 1 项目
- CellSTACK 1 项目
- DermaCult 1 项目
- EasyPick 1 项目
- ELISA 3 项目
- ES-Cult 78 项目
- Falcon 1 项目
- GloCell 1 项目
- GyneCult 1 项目
- HetaSep 1 项目
- Maestro 2 项目
- Matrigel 2 项目
- MegaCult 37 项目
- STEMprep 11 项目
- ALDEFLUOR 237 项目
- AggreWell 82 项目
- ArciTect 38 项目
- BloodStor 2 项目
- BrainPhys 84 项目
- CellAdhere 3 项目
- ClonaCell 107 项目
- CloneR 9 项目
- CryoStor 75 项目
- EC-Cult 1 项目
- EasySep 963 项目
- EpiCult 15 项目
- HemaTox 4 项目
- HepatiCult 32 项目
- Hypothermosol 1 项目
- ImmunoCult 39 项目
- IntestiCult 213 项目
- Lymphoprep 12 项目
- MammoCult 45 项目
- MesenCult 164 项目
- MethoCult 499 项目
- MyeloCult 65 项目
- MyoCult 10 项目
- NaïveCult 1 项目
- NeuroCult 373 项目
- NeuroFluor 3 项目
- PBS-MINI 8 项目
- PancreaCult 11 项目
- PneumaCult 119 项目
- RSeT 13 项目
- ReLeSR 10 项目
- RoboSep 43 项目
- RosetteSep 268 项目
- STEMdiff 193 项目
- STEMscript 1 项目
- STEMvision 7 项目
- SepMate 38 项目
- SmartDish 1 项目
- StemSpan 251 项目
- TeSR 1545 项目
- ThawSTAR 5 项目
- mFreSR 9 项目
- Highway1 7 项目
Show More
Show Less
细胞类型
- B 细胞 229 项目
- CD4+ T细胞 46 项目
- CD8+ T细胞 29 项目
- CHO细胞 15 项目
- HEK-293细胞(人胚肾293细胞) 2 项目
- NK 细胞 162 项目
- PSC衍生 37 项目
- T 细胞 440 项目
- 上皮细胞 143 项目
- 中胚层 5 项目
- 乳腺细胞 95 项目
- 先天性淋巴细胞 32 项目
- 全血 10 项目
- 其他子集 1 项目
- 其他细胞系 10 项目
- 内皮细胞 11 项目
- 内胚层 4 项目
- 前列腺细胞 18 项目
- 单个核细胞 93 项目
- 单核细胞 178 项目
- 多能干细胞 1986 项目
- 小胶质细胞 13 项目
- 巨噬细胞 42 项目
- 巨核细胞 10 项目
- 心肌细胞 21 项目
- 成骨细胞 10 项目
- 星形胶质细胞 14 项目
- 杂交瘤细胞 92 项目
- 树突状细胞(DCs) 118 项目
- 气道细胞 4 项目
- 浆细胞 3 项目
- 淋巴细胞 73 项目
- 癌细胞及细胞系 149 项目
- 癌细胞和细胞系 1 项目
- 白细胞 24 项目
- 白细胞单采样本 13 项目
- 白血病/淋巴瘤细胞 14 项目
- 监管 1 项目
- 真皮细胞 3 项目
- 神经元 1 项目
- 神经干/祖细胞 465 项目
- 神经细胞 12 项目
- 粒细胞及其亚群 96 项目
- 红系细胞 12 项目
- 红细胞 13 项目
- 肌源干/祖细胞 11 项目
- 肝细胞 40 项目
- 肠道细胞 103 项目
- 肾细胞 4 项目
- 肿瘤细胞 27 项目
- 胰腺细胞 17 项目
- 脂肪细胞 6 项目
- 脑肿瘤干细胞 103 项目
- 血小板 4 项目
- 血管生成细胞 1 项目
- 角质形成细胞 1 项目
- 调节性T细胞 10 项目
- 软骨细胞 9 项目
- 造血干/祖细胞 968 项目
- 造血干祖细胞 6 项目
- 造血细胞 4 项目
- 间充质基质细胞 25 项目
- 间充质干/祖细胞 188 项目
- 间充质干祖细胞 1 项目
- 间充质细胞 3 项目
- 骨髓基质细胞 1 项目
- 髓系细胞 135 项目
- 肾脏细胞 8 项目
- PSC衍生上皮细胞 39 项目
- PSC衍生中胚层 25 项目
- PSC衍生内皮细胞 20 项目
- PSC衍生内胚层 28 项目
- PSC衍生心肌细胞 26 项目
- PSC衍生神经细胞 130 项目
- PSC衍生肝细胞 18 项目
- PSC衍生造血干细胞 39 项目
- PSC衍生间充质细胞 27 项目
- 其他T细胞亚型 31 项目
- 呼吸道细胞 96 项目
- 多巴胺能神经元 6 项目
- 小鼠胚胎成纤维细胞 1 项目
- 神经元 201 项目
Show More
Show Less

EasySep™小鼠TIL(CD45)正选试剂盒



沪公网安备31010102008431号